Medicare coverage of drugs specifically for weight loss has been a hot topic for a long time now, but this trend has accelerated with the popularity and effectiveness of the GLP-1 class of drugs (Ozempic). In fact, this may actually become the law by the time of this presentation. This presentation would explore the potential policy routes and the likelihood of this substantial change happening, the potential impact of covering these drugs for weight loss under Part D, as well as the impact on the medical side.
- Future Actuaries
-
Education & Exams
Educational Pathways Associate of the Society of Actuaries (ASA) Fellow of the Society of Actuaries (FSA) Chartered Enterprise Risk Analyst (CERA) Micro-Credentials
- Professional Development
-
Research Institute
Aging & Retirement Artificial Intelligence Catastrophe and Climate COVID-19 Disability Diversity Equity & Inclusion Finance & Investment General Insurance Global Health Care Cost Trends Innovation & Technology Life & Annuities Long-Term Care Mortality & Longevity Predictive Analytics & Modeling Risk Management U.S. Population Valuation/IllustrationsSponsorships Proposal Requests Data Requests Calls for Papers Funding & Grants Competitions & Awards Academic & Student Research
- Communities
-
Tools & Resources
- About SOA
- Future Actuaries
-
Education & Exams
- Professional Development
-
Research Institute
-
Aging & Retirement Artificial Intelligence Catastrophe and Climate COVID-19 Disability Diversity Equity & Inclusion Finance & Investment General Insurance Global Health Care Cost Trends Innovation & Technology Life & Annuities Long-Term Care Mortality & Longevity Predictive Analytics & Modeling Risk Management U.S. Population Valuation/Illustrations
-
- Communities
-
Tools & Resources
-
About SOA
-
Topics in the News